History
Making a better world with innovative data-driven drug discovery and development
2024
Growth Stage
- Attended the JPM Healthcare Conference 2024
2023
Growth Stage
- Selected as a Presenting Company in BioTech Showcase 2023
- Selected as a Presenting Company in Bio CEO & Investor 2023
- Attended the Bio Europe, Spring 2023
- Selected as a Presenting Company in Asia Bio Partnering Forum 2023
- 9 valuable meetings regarding L/O of SBC101 in Bio Korea 2023
- Attended the Bio International Convention 2023
- Selected as the operating company for the Third National New Drug Development Project in 2023
2022
Growth Stage
- Selected as a Presenting Company in Bio Europe 2022
- Attended Bio USA 2022
- 2 Patents submitted: Composition of matter
- Signed a joint R&D agreement with ADDI in UK
- Launched an innovative machine learning & wet lab workflow drug discovery platform, Sapientia
- Changed the Corporate Name to SapiensBio, Inc.
2021
Research and Evaluation Stage
- Novel Target Identification & Validation
- Implementation of an in-house wet lab experimentation system
- Patent submitted: Composition of matter
- Participated in Bio USA 2021
- Started fibrosis & Alzheimer’s disease treatment
- Changed the name from Ailon to SapiensBio, Inc
2019 ~ 2020
Development stage
- Obtained Venture Business and Corporate R&D Institute Certifications
- Invented new AI drug discovery platform, Sapientia
2018
Foundation stage
- Establishment of Ailon, Inc.
